Apollo Hospitals Enterprise Limited vs GlaxoSmithKline Pharmaceuticals Limited

A side-by-side comparison of Apollo Hospitals Enterprise Limited (APOLLOHOSP) and GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

Apollo Hospitals Enterprise Limited vs GlaxoSmithKline Pharmaceuticals Limited are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.

  • Valuation22
  • Profitability04
  • Growth20
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

58.43
P/E ratio
47.10
13.46
P/B ratio
21.22
0.22%
Dividend yield
2.01%
₹135.04
EPS
₹54.52

Profitability

GLAXO takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

20.48%
Return on equity
45.69%
17.31%
Return on capital
62.13%
14.94%
EBITDA margin
34.26%
7.94%
Net margin
27.11%

Growth

APOLLOHOSP takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
5.53%
33.35%
Profit CAGR (3Y)
19.26%

Size & financial health

APOLLOHOSP takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.14L Cr
Market cap
₹43,456 Cr
₹25,229 Cr
Revenue
₹3,822 Cr
₹2,003 Cr
Net profit
₹1,036 Cr
0.90
Debt / equity
0.00
Apollo Hospitals Enterprise Limited
  • + ["Company has delivered good profit growth of 71.0% CAGR over last 5 years", "Company has delivered good sales growth of 19.0% CAGR over last 5 years"]
  • − ["Stock is trading at 11.97 times its book value"]
GlaxoSmithKline Pharmaceuticals Limited
  • + ["Company has delivered good profit growth of 23.7% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 44.1%", "Company has been maintaining a healthy dividend payout of 93.2%", "Company is almost debt free."]
  • − ["Stock is trading at 19.17 times its book value", "The company has delivered a poor sales growth of 5.5% over past five years."]
Apollo Hospitals Enterprise Limited full analysis GlaxoSmithKline Pharmaceuticals Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.